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1386Failure to Achieve a Threshold Dose of CD341CD1101
Progenitor Cells in the Graft Predicts Delayed Platelet
Engraftment after Autologous Stem Cell
Transplantation for Multiple Myeloma
Craig T. Wallington-Beddoe,1,4 David J. Gottlieb,1,2,4 Fran Garvin,2
Vicki Antonenas,2 Mary M. Sartor3To predict platelet engraftment more accurately post autologous stem cell transplantation (SCT), we retro-
spectively analyzed the CD341CD1101 (CD110 or c-mpl, thrombopoietin receptor) content in the grafts of
70 patients undergoing transplantation for multiple myeloma (MM) with an in-house flow cytometric assay.
We found that infusing at least 3.0  104 CD341CD1101 cells/kg clearly separated the cohort into those
who achieved platelet engraftment before or after 21 days. This early megakaryocyte cell marker correlated
more closely with early versus delayed platelet engraftment than CD341measurements. Of the 70 patients,
4 required$ 21 days to achieve platelet transfusion independence. Three of the 4 received aCD341CD1101
cell dose of\3.0 104 cells/kg, whereas 66 of 70 patients who received.3.0 104 CD341CD1101 cells/kg
achieved platelet transfusion independence in\21 days (P\ .001). Infusing .3.0  104 CD341CD1101
cells/kg was sensitive (100%) and specific (75%) for achieving platelet engraftment within 21 days. Patients
with delayed platelet engraftment received a median of 2.28  104 CD341CD1101 cells/kg versus 12.1 
104 cells/kg in those without this complication (P 5 .033). No effect was seen with neutrophil engraftment.
Patients with early engraftment required a median of 1 platelet transfusion post transplant versus 2.5 in those
with late engraftment (P5 .009). A subthreshold absolute CD341CD1101 cell dose in the graft is a reliable
predictor of delayed platelet engraftment, and could be used to guide the timing and number of peripheral
blood stem cell (PBSC) collections for patients with MM undergoing an SCT.
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Multiple myeloma (MM) is a malignant plasma cell
disorder accounting for approximately 10% of all he-
matologic cancers, and is characterized by an excessive
numbers of plasma cells in the bone marrow (BM) and
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/09/1511-0005$36.00/0
6/j.bbmt.2009.06.018annual incidence of MM in the United States is 4.3
new cases per 100,000. It may evolve from an asymp-
tomatic premalignant condition termed monoclonal
gammopathy of undetermined significance (MGUS)
present in over 3% of the population above the age of
50 years, which evolves to myeloma at the rate of 1%
per year [1].Hypercalcemia, anemia, renal damage, im-
paired production of normal immunoglobulin, and in-
creased susceptibility to bacterial infections are
common clinical manifestations of MM, and it is often
also characterized by diffuse osteoporosis. MM is con-
sidered a treatable but incurable disease, with a median
survival of 4 to 5 years [2].
Treatment of MM depends on both age and per-
formance status of the patient. The Intergroupe Fran-
cophone du Myelome (IFM) demonstrated that in
patients \65 years of age and of reasonable perfor-
mance status, high-dose therapy (HDT) followed by
autologous stem cell transplantation (SCT) produced
high rates of complete (CR) and very good partial
Table 1. Details of the 70 Patients (72 Transplants)
Undergoing Autologous Stem Cell Transplantation for Multi-
ple Myeloma
Characteristic Number
Number of patients (transplants) 70 (72)
Age (years)
Median (range) 58 (34-72)
Sex
Male 41
Female 29
Paraprotein isotype
IgG 47
IgA 17
Light chain only 6
Stage at diagnosis (Durie-Salmon)
Stage I 35
Stage II 23
Stage III 12
Lines of therapy prior to transplant
1 50
2 18
>2 2
Remission status prior to transplant
CR 3
PR 32
Stable disease (plateau) 29
Progressive disease 6
Source of stem cells
Peripheral blood 72
Bone marrow 0
Conditioning regimen
Melphalan 140 mg/m2 2
Melphalan 200 mg/m2 69
Melphalan 220 mg/m2 1
No. of transplants/patient
1 68
2 2
No. of collections/patient
1 51
2 15
3 4
CD34+ dose (106/kg)
Median (range) 4.1 (1.1-15.6)
<2.0 4 (5.5%)
$2.0 and <5.0 44 (61%)
$5.0 and <10.0 20 (28%)
$10.0 4 (5.5%)
CD34+CD110+ dose (104/kg)
Median (range) 11.6 (2-128)
Days to platelet engraftment ($20
 109/L)
Median (range) 12.0 (1-34)
Days to ANC >0.5  109/L
Median (range) 13 (8-24)
ANC indicates absolute neutrophil count; CR, complete remission; PR,
partial remission.
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compared with standard-dose chemotherapy alone
[3]. More recently, it has been recognized that older
patients including those above the age of 70 years
with good performance status are also eligible for
high-dose therapy and autologous transplantation
[4,5]. Tandem (or sequential) autologous SCT was
shown by the Arkansas group to increase the percent-
age of patients with CR and PR and improved OS in
a multivariate analysis [6]. In a study that randomized
patients to receive either a single or double autologous
SCT for myeloma, a second autologous SCT pro-
duced a survival benefit in those who failed to achieve
at least a very good partial response after the first trans-
plant [7].
High-dose therapy results in an inevitable period
of post transplant marrow hypoplasia during which
clinical problems of infection and bleeding occur.
The severity of the problems is proportional to the
duration and severity of neutropenia and thrombocy-
topenia. Delayed platelet engraftment presents a par-
ticular problem that results in an increased risk of
hemorrhage and in complications associated with
transfusion of platelets or blood products. In addition,
prolonged thrombocytopenia causes logistic prob-
lems, including increased hospital length of stay and
increases resource utilization because of the need to
obtain donor platelets.
Existing literature strongly supports the notion that
the CD341 content of the stem cell graft is the most
important factor in predicting neutrophil and platelet
engraftment after myeloablative (MA) chemotherapy.
Rapid engraftment of all hemopoietic cell lines is con-
sistently seen when .10  106 CD341 cells/kg are in-
fused, but grafts containing this stem cell amount are
rarely obtained [8]. Engraftment is less reliable at lower
stem cell doses, with one-quarter of patients receiving
\10  106 CD341 cells/kg failing to achieve a platelet
count of 20  109/L before day 21 in one study and an
even higher percentage at the more common cell doses
infused of 1-5  106 cells/kg [8]. As the CD341 cell
count in the stem cell graft falls, the risk of delayed
platelet engraftment rises. However, the measure is
only approximate: in one study, 62% of patients receiv-
ing a CD341 cell dose of\2 106/kg failed to achieve
a platelet count of $50  109/L by day 21, but the
remainder did so despite the low stem cell number
infused [9]. Clearly, a better test is required to predict
those transplant recipients likely to suffer delayed
platelet engraftment, especially in the most common
group receiving CD341 cell doses\5  106 cells/kg.
Although the definition of delayed platelet engraftment
after transplant is an arbitrary one, we have defined de-
layed platelet engraftment as a failure to achieve a plate-
let count of $20  109/L by day 21 after autologous
SCT. A platelet count of 20  109/L represents
a threshold at which the risk of spontaneous bleedingis considered to be low and is considered to be safe
for withholding platelet transfusion.
We previously published a method for predicting
delayed platelet engraftment by quantifying the
number of CD341 cells coexpressing the thrombo-
poietin receptor c-mpl (CD110) within the stem cell
graft. Although CD110 expression on CD341 cells is
not restricted to megakaryocyte precursors [10], bind-
ing of thrombopoietin to c-mpl induces megakaryo-
cyte proliferation and differentiation [11]. Our
laboratory has developed a single-platform flow cyto-
metric assay for enumerating the CD341CD1101
1388 Biol Blood Marrow Transplant 15:1386-1393, 2009C. T. Wallington-Beddoe et al.stem cell content in the graft [12]. Our initial analysis
of 39 patients undergoing autologous peripheral blood
stem cell transplantation (PBSCT) for a variety of he-
matologic malignancies demonstrated that achieving
a threshold of 6  104 CD341CD1101 stem cells/kg
reliably predicted early platelet engraftment [12]. In
this study, we have attempted to validate our previous
findings on amore homogeneous group of patients un-
dergoing autologous SCT for MM. Our data indicate
that within this cohort, achievement of a similar
threshold dose of megakaryocyte progenitors also con-
sistently predicts rapid platelet engraftment.MATERIALS AND METHODS
Patients
We retrospectively analyzed the CD341CD1101
stem cell component of 93 autologous PBSC harvests
for 70 patients with MM processed at our cell process-
ing facility at Westmead Hospital between 2001 and
2008. All patients undergoing PBSC collection and
subsequent stem cell reinfusion for MM during this
period were included in the study. Institutional ethics
approval was given for the analysis. Disease, graft,
and transplant characteristics are shown in Table 1.
Mobilization and Cellular Processing
PBSCs were mobilized using the combination of 4
g/m2 cyclophosphamide (Cy) followed by granulo-
cyte-colony stimulating factor (G-CSF) 10 mg/kg/day
for 10 days before initial stem cell harvest. G-CSF
commenced 48 hours after Cy administration. Apher-
esis was performed using the Cobe Spectra (Caridian
BCT) using a 121 exchange protocol. Collection
went ahead when the patient’s PB white cell count
was .1  109/L and the morning PB CD34 count
reached $20/mL. The required collection target was
2-5  106 CD341 cells/kg. Collection on 1 day was
performed in 51 patients, 2 consecutive collections in
15 patients, and 3 consecutive collections in 4 patients.
All collections were processed in a central laboratory
with uniform cell processing techniques as described
previously [12,13]. Two patients received tandem
transplants. Collections were not split for these trans-
plants, and the 2 patients received the entire harvest
from 3, 2, 1, and 1 collections for the 4 transplants, re-
spectively.
Immunophenotyping
Absolute CD341 cells and CD34 subsets express-
ing c-mpl were enumerated using an in-house single
platform viable CD34 flow cytometric assay as previ-
ously detailed [12,13]. Briefly, for cryopreserved sam-
ples, 10 mL of hemopoietic progenitor cell (HPC)
product, taken from cryovials, was stained with 5mL of CD34 polycoerythrin (PE), 5 mL CD45 fluo-
rescein isothyocyanate (FITC), 10 mL CD110 allo-
phycocyanin (APC), and 10 mL 7-aminoactinomycin
D (7AAD) in a TRUCOUNT tube (antibodies
supplied by BD Bioscience, San Jose, CA) and incu-
bated for 10 minutes at room temperature. There
were no wash steps or lysis agent used in the proce-
dure. An additional 450 mL of phosphate-buffered
saline (PBS) was added to the tube immediately
before analysis by flow cytometry. Data acquisition
was performed within 30 minutes of thawing for all
samples.
Flow cytometry
List mode data was acquired on 2 flow cytometers.
Prior to 2006, data was acquired and analyzed on
a FACS Calibur flow cytometer using Cell Quest 3.1
software (BD Bioscience). Post 2006 all acquisition
and analysis was performed on a Cyan ADP using
Summit 4.2 software (Beckman Coulter, Fullerton,
CA). Instrument performance was validated by acquir-
ing in parallel CD341CD1101 data on 10 PBSC har-
vest samples. The coefficient of variation on these
samples were\ 1% and considered within acceptable
limits.
Gating Strategy for the In-House
Single-Platform Protocol
A modification of the ISHAGE gating strategy
described by Sutherland et al. [14] was used to obtain
the absolute number of CD341CD1101 cells per mi-
crolitre. Briefly, the instrument’s threshold was set on
CD45 FITC expression as this minimized debris and
allowed the enumeration of TRUCOUNT beads.
Viable leukocytes were identified as 7AAD-negative
events and CD1101 expression was determined on
the gated viable CD341 population. Acquisition con-
tinued until a minimum of 100 CD341CD1101 events
were collected (this ensured the number of beads
acquired always exceeded 3000). The number of
CD341CD1101 cells/mL was calculated as follows:
(no. of viable CD341CD1101 cells)  (total no. of
beads per TRUCOUNT tube) divided by (no. of
beads acquired  the sample volume in mL).
Hemopoietic Recovery after BMT
Autologous transplantation was performed fol-
lowing therapy using conditioning chemotherapy at
standard doses (Table 1). Leukocyte engraftment
was defined as the first of 3 consecutive days that neu-
trophils exceeded 0.5  109/L. Platelet engraftment
was taken as the first day of platelet count $20 
109/L on at least 3 occasions, 7 days after the most
recent platelet transfusion (as defined by the Interna-
tional Bone Marrow Transplant Registry). Delayed
platelet engraftment is defined as an unsupported
Figure 1. Correlation between absolute number of CD341 and abso-
lute number of CD341CD1101 cells/kg infused at the time of trans-
plant. R2 5 .46, n 5 72.
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tologous SCT. Platelet infusions were given as single
units of pooled platelets. Infusions were given when
platelet counts decreased below 15  109/L or ac-
cording to clinical needs determined by treating phy-
sicians. Packed red cell transfusions were
administered when the hemoglobin concentration
fell below 80 g/L or at the treating physician’s discre-
tion. Cytokines (G-CSF, erythropoietin, etc.) were
not administered in the posttransplant period, and
antibiotics were commenced at the first febrile neu-
tropenic episode and continued until resolution of
the neutropenia. The first-line antibiotic regimen
consisted of either timentin (ticarcillin 1 clavulanate)
or a fourth-generation cephalosporin in combination
with an aminoglycoside.Figure 2. Number of (A) CD341 cells  106/kg and (B)
CD341CD1101 cells  104/kg harvested on each day of collection for
patients having 2 leukaphereses (n 5 15) or 3 leukaphereses (n 5 4) in
preparation for autologous stem cell transplantation.Statistical Analysis
The statistical software packages SPSS for Win-
dows Version 15 and Prism Version 5 were used to
analyze the data. Fisher’s exact test was used to test
for association between categoric variables and the
Mann-Whitney test to assess for differences in the dis-
tribution of continuous variables between groups. The
CD341CD1101 counts were log transformed to
approximate normality prior to analysis. Analysis of
variance was used to test for differences between the
distributions of the log transformed data in the sub-
groups of interest. Two-tailed tests with a significance
level of\.05 were used throughout. A receiver opera-
tor characteristics (ROC) curve was used to illustrate
the performance of CD110 in predicting early engraft-
ment (\21 versus $21 days).RESULTS
Details of Patients and Cell Numbers in the
Autologous Stem Cell Products
The median age of the 70 patients analyzed was 58
years (range: 34-72 years). All patients undergoing au-
tologous transplantation received at least 1.1  106
CD341 cells/kg of peripherally mobilized stem cells
(Table 1). The median CD341 cell number/kg infused
was 4.1  106/kg (range: 1.1-15.6). The median
CD341CD1101 cell number/kg infused was 11.6 
104/kg (range: 2-128). There was a weak correlation be-
tween the number of CD341 and the number of
CD341CD1101 cells contained within grafts, r25 .46
(Figure 1). There were no statistically significant differ-
ences between the total number of CD341CD1101
stem cells collected from those with stage 1 versus stage
2 versus stage 3 disease prior to transplant (P5 .78), nor
was a statistically significant difference seen between the
Table 2. Details of the 4 Patients with $21 Days to Platelet Engraftment (All 4 Patients Received Cells from a Single Apheresis
Collection)
Patient
Age
(years) Sex
Paraprotein
Isotype
Lines of
Prior Therapy
CD34+ Dose Infused
(106/kg)
CD34+CD110+ Dose
Infused (104/kg)
Platelet Engraftment
(Days)
Neutrophil Engraft-
ment (Days)
1 63 male IgG 1 3.1 2.1 23 14
2 64 male IgA 1 3.7 2.0 34 15
3 54 male IgG 1 3.8 22.9 23 15
4 56 female IgG 1 2.8 2.45 21 13
Figure 3. (A) Number of days to platelet engraftment plotted against
absolute number of CD341CD1101 cells/kg infused at the time of
transplant. Vertical line indicates a threshold of 3.0  104
CD341CD1101 cells/kg and the horizontal line represents 21 days
post transplant. (B) Number of days to platelet engraftment plotted
against absolute number of CD341cells/kg infused at the time of trans-
plant. Vertical line indicates a threshold of 2.0 106 CD341 cells/kg and
the horizontal line represents 21 days post transplant.
1390 Biol Blood Marrow Transplant 15:1386-1393, 2009C. T. Wallington-Beddoe et al.total number of CD341CD1101 cells collected and the
number of prior lines of therapy patients had received (P
5 .51). Fifty percent of those who had received 2 or
more lines of prior therapy did, however, require more
than 1 leukapheresis to obtain a satisfactory stem cell
collection of .2  106 CD341 cells/kg, compared to
18% who received only 1 prior therapy (P 5 .006).
The median number of CD341CD1101 cells  104/
kg obtained from the first, second, and third days of au-
tologous PBSC collections were 12.6 (range: 2-172),
11.2 (range: 3-91), and 11.0 (range: 10-17), whereas
the averages were 30.6, 15.9, and 12.7, respectively.
Those patients (27%) who underwent more than 1 leu-
kapheresis tended to yield a higher number of
CD341CD1101 stem cells in subsequent collections
(Figure 2). In 3 of 4 patients having 3 leukaphereses to
achieve a target CD34 dose of.2  106 CD341 cells/
kg, the number of CD341CD1101 cells harvested in-
creased with each day of apheresis, whereas the harvest
of CD341CD1101 cells increased on the second day
in 12 of the 15 patients who had 2 leukaphereses. The
increase in CD341CD1101 cells exceeded that
observed for CD341 cells (median harvest number
2.4, 3.9, and 2.0  106/kg on days 1, 2, and 3, respec-
tively, for CD341 cells; median harvest number 4.7,
12.2, and 9.5  104/kg on days 1, 2, and 3 for
CD341CD1101 cells).
Platelet Reconstitution Post Autologous
Transplantation
Sixty-six patients became platelet transfusion inde-
pendent within 21 days of transplantation; all received
.3.0  104 CD341CD1101 cells/kg. In all cases,
platelet reconstitution was sustained. No patient
achieving an unsupported platelet count $20  109/
L subsequently developed graft loss with platelet
counts falling below this value. Four patients failed
to achieve an unsupported platelet count of $20 
109/L before day 21, achieving platelet independence
between days 21 and 34 (Table 2 and Figure 3A).
Three of the 4 received a graft containing \3.0 
104 CD341CD1101 cells/kg, whereas the remaining
one received a dose of 22.9  104 CD341CD1101
cells/kg (P\ .001). This patient’s thrombocytopenia
was associated with a prolonged period of high fevers,
rash, and positive blood cultures. Platelet engraftment
occurred at day 23. All 4 patients received an adequateCD341 cell dose of between 2 and 5  106/kg. No
threshold CD341 dose predicting delayed platelet en-
graftment could be identified (Figure 3B). An ROC
curve generated using the absolute number of
CD341CD1101 cells/kg for each patient showed
that .3.0  104 CD341CD1101 cells/kg was highly
sensitive (100%) and specific (75%) for achieving
platelet engraftment within 21 days. Comparing
patients displaying platelet engraftment within 21
Table 3. Engraftment Details Stratified by CD34+ Cell Dose
CD34+ Dose Infused
(106/kg)
Number of
Transplants
Median CD34+CD110+
Dose Infused (104/kg)
Median ANC Recovery
(Days)
Median Platelet
Recovery (Days)
<2 4 8.3 (4.7-10.3) 15.5 (11-19) 18.0 (9-19)
$2 and <5 44 10.3 (2-53.4) 13.0 (8-24) 13.0 (1-34)
$5 and <10 20 22.6 (4.3-56.2) 12.5 (9-21) 11.0 (1-18)
$10 4 60.2 (13.9-128) 16.5 (8-19) 1.0 (1-13)
ANC indicates absolute neutrophil count.
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beyond that time, the former group received a median
of 12.0  104 CD341CD1101 cells/kg (range: 3-128)
compared with 2.3  104 CD341CD1101 cells/kg
(range: 2-22.9) in the latter (P 5 .033). Patients with
$21 days to platelet engraftment received platelet
transfusions more often than those with\21 days to
platelet engraftment (median 2.5, range: 1-9 versus 1,
range: 0-4 respectively, P 5 .009).Engraftment Kinetics According to CD341 Cell
Doses of\2, 2-5, 5-10, and $10  106/kg
We analyzed the engraftment characteristics of pa-
tients receiving varying numbers of CD341 stem cells
(Table 3). Although the correlation between CD341
and CD341CD1101 progenitor cell numbers was
weak, mean CD341CD1101 cell numbers rose with
mean CD341 numbers. The period to absolute
neutrophil recovery of 0.5  109/L did not vary with
CD341 dose infused, but there was a continuous
reduction in the time to platelet recovery as CD341
and CD341CD1101 cell numbers increased (Fig-
ure 4). Four patients received a CD341 stem cell
dose of between 1 and 2 106/kg, at which neutrophil
and platelet engraftment is expected to be unreliable.
Neutrophil engraftment occurred at a median of 15.5
days posttransplant (range: 11-19 days; Table 4). All
of these patients received .3  104 CD341CD1101
cells/kg and all achieved platelet engraftment within
21 days (median 18 days, range: 9-19), 2 of whomFigure 4. Dose effect of increasing numbers of CD341CD1101 cells/
kg on platelet engraftment (bars represent median values).achieved platelet engraftment before neutrophil
engraftment. Sixty-one percent of transplants (44
grafts) contained between 2 and 5  106 CD341
cells/kg with a median time to neutrophil engraftment
of 13 days (range: 8-24) and platelet engraftment of 13
days (range: 1-34). 28% of transplants (20 grafts) con-
tained between 5 and 10  106 CD341 cells/kg with
a median neutrophil engraftment of 12.5 days (range:
9-21) and platelet engraftment of 11 days (range: 1-
18). A total of 5.5% of transplants (4 grafts) contained
.10  106 CD341 cells/kg with a median neutrophil
engraftment of 16.5 days (range: 8-19) and platelet en-
graftment of 1 day (range: 1-13).DISCUSSION
The data generated in this study confirm our previ-
ous findings that reaching a threshold CD341CD1101
stem cell dose predicts rapid platelet engraftment in au-
tologous SCT. Our original data were obtained using
a more heterogeneous patient group, whereas this
study has established that for patients withMMunder-
going autologous SCT, a threshold dose of 3  104
CD341CD1101 stem cells/kg ensures platelet engraft-
ment within 21 days of stem cell infusion. There was
surprisingly close agreement between this value and
the value of 6  104 CD341CD1101 stem cells/kg
that we identified in our previous study, suggesting
that the absolute number of platelet progenitors in-
fused is more important than other factors such as the
number of CD341 cells, the number of cycles, or
type of prior chemotherapy or the state of the bone
marrow microenvironment in determining the speed
of platelet engraftment.
Only5%ofpatients undergoing autologousSCTin
this single center study received a dose of CD341 cells
.10  106/kg, the dose at which rapid neutrophil and
platelet engraftment reliably occurs. At the other ex-
treme, a similar percentage underwent autologous
transplantation with a CD341 cell dose\2  106/kg,
a level at which the chance of delayed neutrophil and
platelet engraftment is considered moderate to high.
None of the 4 patients in this group, all of whom
received .3  104 CD341CD1101 stem cells/kg,
experienceddelayedneutrophil or platelet engraftment,
raising the possibility that the presence of at least
3  104 CD341CD1101 stem cells/kg provides an
Table 4. Engraftment Details of 4 Patients Receiving <2  106 CD34+ Cells/kg
Patient
CD34+ Dose Infused
(106/kg)
CD34+CD110+ Dose
Infused (104/kg)
Neutrophil Engraftment
(Days)
Platelet Engraftment
(Days)
1 1.1 8.3 16 19
2 1.3 8.2 11 9
3 1.6 4.7 19 18
4 1.9 10.3 15 18
Patients 1, 3, and 4 received cells from a single apheresis collection.
Patient 2 received cells from 2 successive apheresis collections.
1392 Biol Blood Marrow Transplant 15:1386-1393, 2009C. T. Wallington-Beddoe et al.additional (orpotentially superior)measureof adequacy
of stemandprogenitor cell numbers for normal engraft-
ment. A larger number of transplants with these low
numbers of CD341 cells will be required to address
this point.
Two thirds of transplants in this study were per-
formed with a CD341 cell dose below 5  106/kg. It
is in this group that the quantitation ofCD341CD1101
cell dose is likely to be most relevant. Three patients
(just under 7% of the group) received \3  104
CD341CD1101 stem cells/kg and experienced delayed
platelet engraftment. An additional patient with
a CD341CD1101 stem cell dose over 3 104/kg expe-
rienced delayed platelet engraftment because of Gram-
positive sepsis and a platelet consumption process. Our
data indicate that even with a CD341 cell dose that is
generally considered adequate for autologous SCT,
the CD341CD1101 cell dose provides useful informa-
tion and can identify a significant minority of patients
destined to require prolonged platelet support. Around
4500 autologous stem cell transplants were performed
in North America for myeloma in 2005 (data from
Center for International Blood andMarrowTransplant
Research [CIBMTR]), so that this assay has the capacity
to detect delayed platelet engraftment in just under 200
patients annually, allowing for collection of increased
numbers of stem cells to avoid this problem. At the
other end of the scale, there was a continuous reduction
in time to platelet recovery with increasing doses of
CD341CD1101 cells that was in contrast to the period
of neutropenia, which did not reduce as CD341 and
CD341CD1101 doses increased. In support of the
independent value of the CD341CD1101 cell dose,
this value correlated poorly with CD341 dose, indicat-
ing that the formermeasuremaywell provide additional
useful information at both high and low CD341 stem
cell numbers.
One important implication of our data is that
transplant physicians may choose to extend the period
of apheresis to achieve the threshold dose of
CD341CD1101 stem cells/kg that ensures rapid
platelet engraftment if this target is not obtained
with initial leukapheresis. The majority of our patients
received stem cells collected with a single leukaphere-
sis. However, data from the 19 patients in this study
who had more than 1 collection indicate that
CD341CD1101 stem cell numbers increased in subse-quent collections, making additional leukaphereses
a worthwhile procedure. Because the number of apher-
eses undertaken in this study was determined by physi-
cians concentrating on obtaining adequate CD341 cell
numbers (.2 106 CD341 cells/kg), we are currently
establishing a protocol that will suggest that transplant
physicians continue requesting the apheresis of
patients undergoing stem cell transplants to achieve
the threshold CD341CD1101 stem cell dose we
have identified. Further follow-up will be required to
determine whether this approach prevents delayed
platelet engraftment in all cases.
We have previously attempted to further refine
this approach by adding or substituting for CD110
alternative megakaryocyte markers including the late
differentiation markers CD41 and CD61. We have
not been able to determine a method that provides
greater sensitivity or specificity than the one we
report here using these markers. Other studies have
reported similar findings with results that provide
less robust correlations with platelet recovery or cor-
relations only with recovery to platelet numbers (eg,
50  109/L)9 that are of less clinical significance
[15-17]. In summary, the methodology we report
here provides a completely sensitive and highly spe-
cific test for predicting delayed platelet engraftment
after autologous SCT for MM in conjunction with
the routine enumeration of CD341 cells. The test is
simple to establish and perform, can be reported rap-
idly, and allows for real-time clinical decision making
about the need for additional leukapheresis. Avoiding
delayed platelet engraftment will reduce the need for
platelet and blood product transfusion, reduce in-
hospital time, and allow for more rapid recovery after
transplantation.ACKNOWLEDGMENTS
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